JPMorgan Chase & Co. Has $431.14 Million Holdings in SPDR S&P Biotech ETF (XBI)

JPMorgan Chase & Co. raised its position in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 56.6% in the first quarter, HoldingsChannel reports. The institutional investor owned 4,761,913 shares of the exchange traded fund’s stock after buying an additional 1,720,255 shares during the period. JPMorgan Chase & Co. owned about 0.10% of SPDR S&P Biotech ETF worth $431,143,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Deutsche Bank AG purchased a new stake in SPDR S&P Biotech ETF during the fourth quarter valued at about $139,893,000. Q3 Asset Management purchased a new stake in SPDR S&P Biotech ETF during the first quarter valued at about $3,285,000. Duality Advisers LP purchased a new stake in SPDR S&P Biotech ETF during the fourth quarter valued at about $51,363,000. Main Management ETF Advisors LLC lifted its stake in SPDR S&P Biotech ETF by 6.1% during the fourth quarter. Main Management ETF Advisors LLC now owns 266,400 shares of the exchange traded fund’s stock valued at $19,114,000 after buying an additional 15,300 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. lifted its stake in SPDR S&P Biotech ETF by 4.7% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 219,221 shares of the exchange traded fund’s stock valued at $15,729,000 after buying an additional 9,784 shares in the last quarter.

XBI stock opened at $82.56 on Monday. SPDR S&P Biotech ETF has a one year low of $64.38 and a one year high of $101.55.

TRADEMARK VIOLATION WARNING: This news story was posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.baseballdailydigest.com/news/2019/05/20/jpmorgan-chase-co-has-431-14-million-holdings-in-spdr-sp-biotech-etf-xbi.html.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

See Also: Insider Trading

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.